Функция липопротеинов высокой плотности при различных патологических состояниях

В обзоре рассмотрены изменения структуры и функции липопротеинов высокой плотности (ЛВП), играющие важную роль в патогенезе ряда хронических заболеваний, так или иначе стимулирующих развитие атеросклероза. Доказано, что функция ЛВП нарушается при ряде генетических и приобретенных заболеваний, ведущих к дислипидемии и связанных с повышенным сердечно-сосудистым риском, таких как семейная гиперхолестеринемия, ожирение, метаболический синдром, хроническая болезнь почек, сахарный диабет, воспалительные и аутоиммунные заболевания.

1. Soria-Florido M. T., Schröder H., Grau M. et al. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis // Atherosclerosis. – 2020. – Vol. 302. – P. 36–42. DOI: 10.1016/j.atherosclerosis.2020.04.015.

2. Khera A. V., Cuchel M., de la Llera-Moya M. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis // N. Engl. J. Med. – 2011. – Vol. 364. – P. 127–135. DOI: 10.1056/NEJMoa1001689.

3. Перова Н. В. Атеромаркеры липопротеинов высокой плотности. Часть I. Липопротеины высокой плотности: структура, состав, физико-химические и физиологические антиатерогенные свойства, их механизмы и маркеры (обзор литературы) // Профилактическая медицина. – 2017. – Т. 20, № 3. – С. 47–54.

4. Agarwala A. P., Rodrigues A., Risman M. et al. High-Density Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. – 2015. – Vol. 35. – P. 1515–1519. DOI: 10.1161/ATVBAHA.115.305504.

5. Thakkar H., Vincent V., Roy A et al. HDL functions and their interaction in patients with ST elevation myocardial infarction: A case control study // Lipids Health Dis. – 2020. – Vol. 19. – P. 75. DOI: 10.1186/s12944-020-01260-4.

6. Agarwala A. P., Rodrigues A., Risman M. et al. HighDensity Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. – 2015. – Vol. 35. – P. 1515–1519. DOI: 10.1161/ATVBAHA.115.305504.

7. Soria-Florido M. T., Castañer O., Lassale C. et al. Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study // Circulation. – 2020. – Vol. 141, № 6. – P. 444–453. DOI: 10.1161/CIRCULATIONAHA.119.041658.

8. Christensen J. J., Narverud I., Ruuth M. et al. Children with familial hypercholesterolemia display changes in LDL and HDL function: A cross-sectional study // J Intern Med. – 2021. – Vol. 290, № 5. – P. 1083–1097. DOI: 10.1111/joim.13383.

9. Ottestad I. O., Halvorsen B., Balstad T. R. et al. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux // J. Nutr. – 2006. – Vol. 136. – P. 877–881. DOI: 10.1093/jn/136.4.877.

10. Hussein H., Saheb S., Couturier M. et al. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis // J Clin Lipidol. – 2016. – Vol. 10, № 1. – P. 124–33. DOI: 10.1016/j.jacl.2015.10.006.

11. Talbot C. P. J., Plat J., Joris P. J. et al. HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men // Atherosclerosis. – 2018. – Vol. 274. – P. 23–28. DOI: 10.1016/j.atherosclerosis.2018.04.029.12.

12. Vazquez E., Sethi A. A., Freeman L. et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women // Am. J. Cardiol. – 2012. – Vol. 109. – P. 527–532. DOI: 10.1016/j.amjcard. 2011.10.008.

13. Marsche G., Zelzer S., Meinitzer A. et al. Adiponectin predicts high-density lipoprotein cholesterol efflux capacity in adults irrespective of body mass index and fat distribution // J. Clin. Endocrinol. Metab. – 2017. – Vol. 102. – P. 4117–4123. DOI: 10.1210/jc.2017-00933.

14. Успенский Ю. П., Петренко Ю. В., Гулунов З. Х. и др. Метаболический синдром. Учебное пособие. – СПб., 2017. – 60 с.

15. Stadler J. T., Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function // Int. J. Mol. Sci. – 2020. – Vol. 21. – P. 8985. DOI: 10.3390/ijms21238985.

16. Wang H. H., Lee D. K., Liu M. et al. Novel insights into the pathogenesis and management of the metabolic syndrome // Pediatr. Gastroenterol. Hepatol. Nutr. – 2020. – Vol. 23. – P. 189–230. DOI: 10.5223/pghn.2020.23.3.189.

17. Gall J., Frisdal E., Bittar R. et al. Association of cholesterol efflux capacity with clinical features of metabolic syndrome: Relevance to atherosclerosis // J. Am. Heart Assoc. – 2016. – Vol. 5. – P. 1–13. DOI: 10.1161/JAHA.116.004808.1007/s00592-015-0824-y.

18. Nur Zati Iwani A. K., Jalaludin M. Y., Yahya A. et al. TG: HDL-C ratio as insulin resistance marker for metabolic syndrome in children with obesity // Front Endocrinol (Lausanne). – 2022. – Vol. 13. – P. 852290. DOI: 10.3389/fendo.2022.852290.

19. Podkowińska A., Formanowicz D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease // Antioxidants. – 2020. – Vol. 9. – P. 752. DOI: 10.3390/antiox9080752.

20. Rysz J., Gluba-Brzózka A., Rysz-Górzyńska M., Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease // Int. J. Mol. Sci. – 2020. – Vol. 21. – P. 601. DOI: 10.3390/ijms21020601.

21. Meier S. M., Wultsch A., Hollaus M. et al. Effect of chronic kidney disease on macrophage cholesterol efflux // Life Sci. – 2015. – Vol. 136. – P. 1–6. DOI: 10.1016/j.lfs.2015.06.005.

22. Gipson G. T., Carbone S., Wang J. et al. Impaired delivery of cholesterol effluxed from macrophages to hepatocytes by serum from CKD patients may underlie increased cardiovascular disease risk // Kidney Int. Reports. – 2020. – Vol. 5. – P. 199–210. DOI: 10.1016/j.ekir.2019.11.003.

23. Lightbody R. J., Taylor J. M. W., Dempsie Y., Graham A. MicroRNA sequences modulating inflammation and lipid accumulation in macrophage “foam” cells: Implications for atherosclerosis // World J. Cardiol. – 2020. – Vol. 12. – P. 303–333. DOI: 10.4330/wjc.v12.i7.303.

24. Nazir S., Jankowski V., Bender G. et al. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! // Adv. Drug Deliv. Rev. – 2020. – Vol. 159. – P. 94–119. DOI: 10.1016/j.addr.2020.10.006.

25. Tanaka S., Couret D., Tran-Dinh A. et al. High-density lipoproteins during sepsis: From bench to bedside // Crit. Care. – 2020. – Vol. 24. – P. 1–11. DOI: 10.1186/s13054-020-02860-3.

26. Sharma N. K., Tashima A. K., Brunialti M. K. C. et al. Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia // Sci. Rep. – 2017. – Vol. 7. – P. 1–13. DOI: 10.1038/s41598-017-15755-1.

27. Quevedo-Abeledo J. C., Sánchez-Pérez H., Tejera-Segura B. et al. Differences in HDL-cholesterol efflux capacity between patients with systemic lupus erythematosus and rheumatoid arthritis // Arthritis Care Res. – 2021. – Vol. 73, № 11. – P. 1590–1596. DOI: 10.1002/acr.24407.

28. Hollan I., Meroni P. L., Ahearn J. M. et al. Cardiovascular disease in autoimmune rheumatic diseases // Autoimmun. Rev. – 2013. – Vol. 12. – P. 1004–1015. DOI: 10.1016/j.autrev.2013.03.013.

29. Ferraz-Amaro I., Hernández-Hernández M. V., Armas-González E. et al. HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients // Clin. Rheumatol. – 2020. – Vol. 39. – P. 1871–1880. DOI: 10.1007/s10067-020-04961-4.

30. Sánchez-Pérez H., Quevedo-Abeledo J. C., de Armas-Rillo L. et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis // Rheumatology. – 2020. – Vol. 59. – P. 2847–2856. DOI: 10.1093/rheumatology/keaa038.